Akari Therapeutics Plc cotiza a 8.54 USD y tiene una capitalización bursátil de $20M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | — | — | $-1.06 | $-3.92 |
| Estimado | $-0.66 | $-1.80 | $-4.40 | $-4.80 |
| Sorpresa | — | — | +75.9% | +18.3% |
| Métrica | AKTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -61.1% | -40.4% | -20.7% |
| ROA | -36.1% | -32.0% | -4.1% |
| Current Ratio | 0.44 | 2.84 | -2.40 |
| Debt / Equity | — | 0.28 | — |